Inflammatory Bowel Disease
Conditions
Brief summary
IL-22 is an IL-10 family cytokine that plays major actions to increase intestinal epithelial barrier function and regeneration during experimental colitis. IL-22 binding protein is a small, soluble, and secreted protein potently inhibiting IL-22 actions through preventing the binding with IL-22 Recepteur. This study aims at characterizing how IL-22 binding protein is regulated in Inflammatory bowel disease to better understand the way IL-22 acts on epithelial cells during flares of the disease.
Interventions
OTHERNon interventional study
Sponsors
Nantes University Hospital
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Crohn's disease or Ulcerative colitis 2. Healthy controls paired for age and sex 3. Samples availability in the biobank 4. Signed consent 5. No (Immune Mediated Inflammatory Disorders other than Inflammatory bowel disease 6. No other conditions predicted or known to affect IL-22/IL-22 recepteur /IL-22 binding protein regulation 7. Availability of clinical data 8. Age \>18 y.o. 9. No pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Regulation of Interleukine 22 binding protein expression in Crohn's disease or Ulcerative colitis | 1 day |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORJérome Martin
Nantes University Hospital
Outcome results
None listed